Methemoglobin formation by triapine, di-2-pyridylketone-4,4-dimethyl-3- thiosemicarbazone (Dp44mT), and other anticancer thiosemicarbazones: Identification of novel thiosemicarbazones and therapeutics that prevent this effect

Molecular Pharmacology

Volumn 82, Issue 1, 2012, Pages 105-114

  Quach, Patricia ^a   Gutierrez, Elaine ^a   Basha, Maram Talal ^b   Kalinowski, Danuta S ^a   Sharpe, Philip C ^b   Lovejoy, David B ^a   Bernhardt, Paul V ^b   Jansson, Patric J ^a   Richardson, Des R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ASCORBIC ACID; DEFEROXAMINE; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; IRON COMPLEX; METHEMOGLOBIN; METMYOGLOBIN; OXYHEMOGLOBIN; THIOSEMICARBAZONE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL LYSATE; CHELATION; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; MOUSE; NONHUMAN; OXIDATION; PRIORITY JOURNAL;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; ASCORBIC ACID; CELL PROLIFERATION; DEFEROXAMINE; DRUG INTERACTIONS; ERYTHROCYTES; HUMANS; IRON; IRON CHELATING AGENTS; KINETICS; METHEMOGLOBIN; MICE; OXIDATION-REDUCTION; OXYHEMOGLOBINS; PYRIDINES; THIOSEMICARBAZONES;

EID: 84862583681     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.078964     Document Type: Article

References (48)

1. Bakan DA, Saltman P, Thériault Y, and Wright PE (1991) Kinetics and mechanisms of reduction of Cu(II) and Fe(III) complexes by soybean leghemoglobin α. Biochem Biophys Acta 1079:182-196.
2. Bernhardt PV, Sharpe PC, Islam M, Lovejoy DB, Kalinowski DS, and Richardson DR (2009) Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem 52:407-415.
3. Chaston TB, Lovejoy DB, Watts RN, and Richardson DR (2003) Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 9:402-414. (Pubitemid 36109758)
4. Dötsch J, Demirakça S, Hahn D, Katz N, Kühl PG, and Rascher W (1999) Accuracy of methemoglobin measurements: comparison of six different commercial devices and one manual method. Crit Care Med 27:1191-1194. (Pubitemid 29314334)
5. Eguchi LA and Saltman P (1984) The aerobic reduction of Fe(III) complexes by hemoglobin and myoglobin. J Biol Chem 259:14337-14338. (Pubitemid 15222243)
6. Eguchi LA and Saltman P (1987) Kinetics and mechanisms of metal reduction by hemoglobin. 1. Reduction of iron(III) complexes. Inorg Chem 26:3665-3669.
7. Galaris D, Cadenas E, and Hochstein P (1989) Redox cycling of myoglobin and ascorbate: a potential protective mechanism against oxidative reperfusion injury in muscle. Arch Biochem Biophys 273:497-504. (Pubitemid 19222002)
8. George P and Stratmann CJ (1952) The oxidation of myoglobin to metmyoglobin by oxygen. I. Biochem J 51:103-108.
9. Gibson QH (1943) The reduction of methaemoglobin by ascorbic acid. Biochem J 37:615-618.
10. Giulivi C and Cadenas E (1993) The reaction of ascorbic acid with different heme iron redox states of myoglobin. Antioxidant and prooxidant aspects. FEBS Lett 332: 287-290. (Pubitemid 23305342)
11. Gojo I, Tidwell ML, Greer J, Takebe N, Seiter K, Pochron MF, Johnson B, Sznol M, and Karp JE (2007) Phase I and pharmacokinetic study of Triapine, a potent ribonucleotide reductase inhibitor, in adults with advanced hematologic malignancies. Leuk Res 31:1165-1173.
12. Gourlain H, Buneaux F, Borron SW, Gouget B, and Levillain P (1997) Interference of methylene blue with CO-oximetry of hemoglobin derivatives. Clin Chem 43:1078-1080.
13. Gunther MR, Sampath V, and Caughey WS (1999) Potential roles of myoglobin autoxidation in myocardial ischemia-reperfusion injury. Free Radic Biol Med 26:1388-1395. (Pubitemid 29302271)
14. Harrington JP and Hicks RL (1994) Spectral analysis of Fe(III)-complex reduction by hemoglobin: possible mechanisms of interaction. Int J Biochem 26:1111-1117.
15. Hegetschweiler K, Saltman P, Dalvit C, and Wright PE (1987) Kinetics and mechanisms of the oxidation of myoglobin by Fe(III) and Cu(II) complexes. Biochem Biophys Acta 912:384-397. (Pubitemid 17066097)
16. Jansson PJ, Sharpe PC, Bernhardt PV, and Richardson DR (2010) Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity. J Med Chem 53:5759-5769.
17. Kalinowski DS and Richardson DR (2005) The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547-583. (Pubitemid 43036441)
18. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV, and Richardson DR (2007) Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem 50:3716-3729. (Pubitemid 47195478)
19. Knox JJ, Hotte SJ, Kollmannsberger C, Winquist E, Fisher B, and Eisenhauer EA (2007) Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161). Invest New Drugs 25:471-477. (Pubitemid 47222906)
20. Kovacevic Z, Chikhani S, Lovejoy DB, and Richardson DR (2011) Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol 80:598-609.
21. Kowol CR, Trondl R, Heffeter P, Arion VB, Jakupec MA, Roller A, Galanski M, Berger W, and Keppler BK (2009) Impact of metal coordination on cytotoxicity of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine) and novel insights into terminal dimethylation. J Med Chem 52:5032-5043.
22. Kunos CA, Waggoner S, von Gruenigen V, Eldermire E, Pink J, Dowlati A, and Kinsella TJ (2010) Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res 16:1298-1306.
23. Liu MC, Lin TS, and Sartorelli AC (1992) Synthesis and antitumor activity of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J Med Chem 35:3672-3677.
24. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, Mo YY, et al. (2012) N-myc downstream regulated gene 1 modulates Wnt-β-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med 4:93-108.
25. Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P, and Richardson DR (2011) Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res 71:5871-5880.
26. Mansouri A and Lurie AA (1993) Concise review: methemoglobinemia. Am J Hematol 42:7-12. (Pubitemid 23008305)
27. Mauk AG and Gray HB (1979) Analysis of the kinetics of electron transfer reactions of hemoglobin and myoglobin with inorganic complexes. Biochem Biophys Res Commun 86:206-210. (Pubitemid 9075586)
28. Mouawad L, Maréchal JD, and Perahia D (2005) Internal cavities and ligand passageways in human hemoglobin characterized by molecular dynamics simulations. Biochem Biophys Acta 1724:385-393. (Pubitemid 41080046)
29. Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, and Sznol M (2003) Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 9:4092-4100. (Pubitemid 37204025)
30. Odenike OM, Larson RA, Gajria D, Dolan ME, Delaney SM, Karrison TG, Ratain MJ, and Stock W (2008) Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs 26:233-239.
31. Prus E and Fibach E (2008) The labile iron pool in human erythroid cells. Br J Haematol 142:301-307. (Pubitemid 351987327)
32. Prus E and Fibach E (2010) Effect of iron chelators on labile iron and oxidative status of thalassaemic erythroid cells. Acta Haematol 123:14-20.
33. Rao VA, Klein SR, Agama KK, Toyoda E, Adachi N, Pommier Y, and Shacter EB (2009) The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIα in breast cancer cells. Cancer Res 69:948-957.
34. Rao VA, Zhang J, Klein SR, Espandiari P, Knapton A, Dickey JS, Herman E, and Shacter EB (2011) The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats. Cancer Chemother Pharmacol 68:1125-1134.
35. Raymond FA and Weinshilboum RM (1975) Microassay of human erythrocyte catechol-O-methyltransferase: removal of inhibitory calcium ion with chelating resin. Clin Chim Acta 58:185-194.
36. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M, and Bernhardt PV (2006) Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem 49:6510-6521. (Pubitemid 44657445)
37. Riches AC, Sharp JG, Thomas DB, and Smith SV (1973) Blood volume determination in the mouse. J Physiol 228:279-284.
38. 2 bonding in myoglobin and hemoglobin: A new molecular paradigm. Prog Biophys Mol Biol 91:83-162.
39. Sullivan SG and Stern A (1982) Effects of ascorbate on methemoglobin reduction in intact red cells. Arch Biochem Biophys 213:590-594. (Pubitemid 12102628)
40. Szuber N, Buss JL, Soe-Lin S, Felfly H, Trudel M, and Ponka P (2008) Alternative treatment paradigm for thalassemia using iron chelators. Exp Hematol 36:773-785.
41. Traynor AM, Lee JW, Bayer GK, Tate JM, Thomas SP, Mazurczak M, Graham DL, Kolesar JM, and Schiller JH (2010) A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503. Invest New Drugs 28:91-97.
42. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, and Sznol M (2004) Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 22:1553-1563. (Pubitemid 41079792)
43. Weis W (1975) Ascorbic acid and biological systems. Ascorbic acid and electron transport. Ann NY Acad Sci 258:190-200.
44. Whitnall M, Howard J, Ponka P, and Richardson DR (2006) A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci USA 103:14901-14906. (Pubitemid 44527826)
45. Winterbourn CC and Carrell RW (1977) Oxidation of human haemoglobin by copper. Mechanism and suggested role of the thiol group of residue β-93. Biochem J 165:141-148. (Pubitemid 8136895)
46. Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D, and Sznol M (2004) A phase I trial of 3-aminopyridine-2- carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 54:331-342. (Pubitemid 39304428)
47. Yu Y, Kalinowski DS, Kovacevic Z, Siafakas AR, Jansson PJ, Stefani C, Lovejoy DB, Sharpe PC, Bernhardt PV, and Richardson DR (2009) Thiosemicarbazones from the old to new: iron chelators that are more than just ribonucleotide reductase inhibitors. J Med Chem 52:5271-5294.
48. Yuan J, Lovejoy DB, and Richardson DR (2004) Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104:1450-1458. (Pubitemid 39166524)